HCPCS Level II code J9352 represents the injectable antineoplastic agent trabectedin, billed in increments of 0.1 mg. This drug-specific code is used when reporting administration of trabectedin in oncology care and is relevant for facility and professional billing in outpatient infusion settings. Nationally, precise coding of high-cost oncology drugs like trabectedin affects payment accuracy, utilization tracking, and access to specialty therapies.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9352 denotes clinically and operationally, typical sites of service for administration, and which major payers are part of the comparative review. The publication outlines benchmarks and coverage patterns where available, summarizes relevant billing practices for oncology infusions, and highlights policy updates and payer considerations that influence reimbursement and prior authorization workflows.

This summary is intended to orient billing staff, oncology pharmacists, and revenue cycle managers to the clinical purpose of the code, the payer landscape, and the types of benchmarking and policy content included in the full publication. Data not available in the input is noted where applicable in detailed sections.